Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine

J. T. Ungerleider, T. Andrysiak, L. Fairbanks, James E Goodnight Jr, G. Sarna, K. Jamison

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Delta-9-tetrahydrocannabinol (THC) and prochlorperazine (Compazine) were found to be equally efficacious in reducing nausea and vomiting associated with cancer chemotherapy across a wide range of chemotherapeutic regimens and tumor types. Both drugs were administered orally one hour before chemotherapy, then every four hours for a total of four doses. Compazine was administered in a fixed dose of 10 mg; THC was administered by body surface area (BSA): BSA < 1.4 m2 = 7.5 mg; BSA 1.4-1.8 m2 = 10 mg; and BSA > 1.8 m2 = 12.5 mg. Two hundred and fourteen subjects (75% of whom had previously received Compazine with varying results) were evaluated employing a double-blind, crossover design. Additional parameters evaluated were study drug effects on appetite, food intake, mood, activity, relaxation, interaction, and concentration. There were significant drug effects with THC: less ability to concentrate (P < 0.01), less social interaction (P < 0.05), and less activity (P < 0.05). There were no significant differences between the two drugs in the level of food intake or appetite. Patients of all ages did equally well on both drugs. Neither past marijuana use nor past Compazine use were related to study drug efficacy. Those patients who correctly identified their THC cycle did better on THC versus those who could not correctly identify which antiemetic they had received (P < 0.05). There were more drug-related effects associated with THC, but these did not reduce the patients' preference for the drug, and were associated with nausea reduction (P < 0.05).

Original languageEnglish (US)
Pages (from-to)636-645
Number of pages10
JournalCancer
Volume50
Issue number4
DOIs
StatePublished - 1982

Fingerprint

Prochlorperazine
Dronabinol
Cannabis
Drug Therapy
Pharmaceutical Preparations
Neoplasms
Body Surface Area
Appetite
Nausea
Eating
Aptitude
Antiemetics
Patient Preference
Interpersonal Relations
Cross-Over Studies
Vomiting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine. / Ungerleider, J. T.; Andrysiak, T.; Fairbanks, L.; Goodnight Jr, James E; Sarna, G.; Jamison, K.

In: Cancer, Vol. 50, No. 4, 1982, p. 636-645.

Research output: Contribution to journalArticle

Ungerleider, J. T. ; Andrysiak, T. ; Fairbanks, L. ; Goodnight Jr, James E ; Sarna, G. ; Jamison, K. / Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine. In: Cancer. 1982 ; Vol. 50, No. 4. pp. 636-645.
@article{83cc83df3821425d96572ecc6bb8ba35,
title = "Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine",
abstract = "Delta-9-tetrahydrocannabinol (THC) and prochlorperazine (Compazine) were found to be equally efficacious in reducing nausea and vomiting associated with cancer chemotherapy across a wide range of chemotherapeutic regimens and tumor types. Both drugs were administered orally one hour before chemotherapy, then every four hours for a total of four doses. Compazine was administered in a fixed dose of 10 mg; THC was administered by body surface area (BSA): BSA < 1.4 m2 = 7.5 mg; BSA 1.4-1.8 m2 = 10 mg; and BSA > 1.8 m2 = 12.5 mg. Two hundred and fourteen subjects (75{\%} of whom had previously received Compazine with varying results) were evaluated employing a double-blind, crossover design. Additional parameters evaluated were study drug effects on appetite, food intake, mood, activity, relaxation, interaction, and concentration. There were significant drug effects with THC: less ability to concentrate (P < 0.01), less social interaction (P < 0.05), and less activity (P < 0.05). There were no significant differences between the two drugs in the level of food intake or appetite. Patients of all ages did equally well on both drugs. Neither past marijuana use nor past Compazine use were related to study drug efficacy. Those patients who correctly identified their THC cycle did better on THC versus those who could not correctly identify which antiemetic they had received (P < 0.05). There were more drug-related effects associated with THC, but these did not reduce the patients' preference for the drug, and were associated with nausea reduction (P < 0.05).",
author = "Ungerleider, {J. T.} and T. Andrysiak and L. Fairbanks and {Goodnight Jr}, {James E} and G. Sarna and K. Jamison",
year = "1982",
doi = "10.1002/1097-0142(19820815)50:4<636::AID-CNCR2820500404>3.0.CO;2-4",
language = "English (US)",
volume = "50",
pages = "636--645",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Cannabis and cancer chemotherapy. A comparison of oral delta-9-THC and prochlorperazine

AU - Ungerleider, J. T.

AU - Andrysiak, T.

AU - Fairbanks, L.

AU - Goodnight Jr, James E

AU - Sarna, G.

AU - Jamison, K.

PY - 1982

Y1 - 1982

N2 - Delta-9-tetrahydrocannabinol (THC) and prochlorperazine (Compazine) were found to be equally efficacious in reducing nausea and vomiting associated with cancer chemotherapy across a wide range of chemotherapeutic regimens and tumor types. Both drugs were administered orally one hour before chemotherapy, then every four hours for a total of four doses. Compazine was administered in a fixed dose of 10 mg; THC was administered by body surface area (BSA): BSA < 1.4 m2 = 7.5 mg; BSA 1.4-1.8 m2 = 10 mg; and BSA > 1.8 m2 = 12.5 mg. Two hundred and fourteen subjects (75% of whom had previously received Compazine with varying results) were evaluated employing a double-blind, crossover design. Additional parameters evaluated were study drug effects on appetite, food intake, mood, activity, relaxation, interaction, and concentration. There were significant drug effects with THC: less ability to concentrate (P < 0.01), less social interaction (P < 0.05), and less activity (P < 0.05). There were no significant differences between the two drugs in the level of food intake or appetite. Patients of all ages did equally well on both drugs. Neither past marijuana use nor past Compazine use were related to study drug efficacy. Those patients who correctly identified their THC cycle did better on THC versus those who could not correctly identify which antiemetic they had received (P < 0.05). There were more drug-related effects associated with THC, but these did not reduce the patients' preference for the drug, and were associated with nausea reduction (P < 0.05).

AB - Delta-9-tetrahydrocannabinol (THC) and prochlorperazine (Compazine) were found to be equally efficacious in reducing nausea and vomiting associated with cancer chemotherapy across a wide range of chemotherapeutic regimens and tumor types. Both drugs were administered orally one hour before chemotherapy, then every four hours for a total of four doses. Compazine was administered in a fixed dose of 10 mg; THC was administered by body surface area (BSA): BSA < 1.4 m2 = 7.5 mg; BSA 1.4-1.8 m2 = 10 mg; and BSA > 1.8 m2 = 12.5 mg. Two hundred and fourteen subjects (75% of whom had previously received Compazine with varying results) were evaluated employing a double-blind, crossover design. Additional parameters evaluated were study drug effects on appetite, food intake, mood, activity, relaxation, interaction, and concentration. There were significant drug effects with THC: less ability to concentrate (P < 0.01), less social interaction (P < 0.05), and less activity (P < 0.05). There were no significant differences between the two drugs in the level of food intake or appetite. Patients of all ages did equally well on both drugs. Neither past marijuana use nor past Compazine use were related to study drug efficacy. Those patients who correctly identified their THC cycle did better on THC versus those who could not correctly identify which antiemetic they had received (P < 0.05). There were more drug-related effects associated with THC, but these did not reduce the patients' preference for the drug, and were associated with nausea reduction (P < 0.05).

UR - http://www.scopus.com/inward/record.url?scp=0019950055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019950055&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19820815)50:4<636::AID-CNCR2820500404>3.0.CO;2-4

DO - 10.1002/1097-0142(19820815)50:4<636::AID-CNCR2820500404>3.0.CO;2-4

M3 - Article

VL - 50

SP - 636

EP - 645

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -